Skip to content

Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea

Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00669929
Enrollment
200
Registered
2008-05-01
Start date
2008-05-31
Completion date
2009-06-30
Last updated
2009-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cost-Effectiveness, Gastroenteritis, Rotavirus Vaccines

Keywords

Cost effectiveness analysis of rotavirus vaccination

Brief summary

The primary objective of the proposed project is to estimate the economic impact of a national rotavirus immunization program in preventing rotavirus diarrhea among Korean children.

Detailed description

Rotavirus is the leading cause of severe acute diarrhea or gastroenteritis among young children worldwide. In the first 5 years of life, about 90% of children experience at least one episode of rotavirus infection.Each year, rotavirus diarrhea is responsible for 440,000 deaths, 2 million hospitalizations, and 25 million outpatient visits among children younger than 5 years worldwide. In South Korea, rotavirus diarrhea rarely causes mortality, but it cause significant morbidity. A recent population-based study in Korea has estimated that the annual incidence of rotavirus diarrhea accounts for 56.9 cases per 1,000 children less than 5 years old. Oral, live pentavalent human-bovine reassortant rotavirus vaccine has been developed and licensed for the use of preventing rotavirus disease in many countries. Yet, there has been no research done to assess the impact of national rotavirus immunization program in Korea. It is expected that systematic appraisal on the national burden of rotavirus infection and potential public health and economic benefits of rotavirus vaccination for children in Korea will assists health policy makers to set a priority for the prevention of this disease.

Interventions

None listed

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Severance Hospital
CollaboratorOTHER
Yonsei University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 5 Years
Healthy volunteers
No

Inclusion criteria

* children aged under 5 years and diagnosed as acute gastroenteritis

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
patients' costone year

Countries

South Korea

Contacts

Primary ContactDong Soo Kim, MD, PhD
dskim6634@yuhs.ac82-2-2228-2005
Backup ContactKi Hwan Kim, MD
khkim99@yuhs.ac82-2-2227-4188

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026